🚀 VC round data is live in beta, check it out!
Sino Biological Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sino Biological and similar public comparables like AbCellera, ACROBiosystems, Evotec, PolyPeptide and more.
Sino Biological Overview
About Sino Biological
Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
Founded
2016
HQ
Employees
N/A
Website
Financials (FY)
EV
$877M
Sino Biological Financials
Sino Biological reported last fiscal year revenue of $103M and EBITDA of $40M.
In the same fiscal year, Sino Biological generated $75M in gross profit, $40M in EBITDA, and $22M in net income.
Revenue (LTM)
Sino Biological P&L
In the most recent fiscal year, Sino Biological reported revenue of $103M and EBITDA of $40M.
Sino Biological expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $103M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $75M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 73% | XXX | XXX | XXX |
| EBITDA | — | XXX | $40M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 15% | XXX | XXX | XXX |
| Net Profit | — | XXX | $22M | XXX | XXX | XXX |
| Net Margin | — | XXX | 21% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sino Biological Stock Performance
Sino Biological has current market cap of $1B, and enterprise value of $877M.
Market Cap Evolution
Sino Biological's stock price is $11.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $877M | $1B | 0.0% | XXX | XXX | XXX | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSino Biological Valuation Multiples
Sino Biological trades at 8.6x EV/Revenue multiple, and 21.9x EV/EBITDA.
EV / Revenue (LTM)
Sino Biological Financial Valuation Multiples
As of April 19, 2026, Sino Biological has market cap of $1B and EV of $877M.
Equity research analysts estimate Sino Biological's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sino Biological has a P/E ratio of 62.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $877M | XXX | $877M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 21.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 57.3x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11.7x | XXX | XXX | XXX |
| P/E | — | XXX | 62.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 132.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sino Biological Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sino Biological Margins & Growth Rates
Sino Biological's revenue in the last fiscal year grew by 14%.
Sino Biological Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 16% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sino Biological Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sino Biological | XXX | XXX | XXX | XXX | XXX | XXX |
| AbCellera | XXX | XXX | XXX | XXX | XXX | XXX |
| ACROBiosystems | XXX | XXX | XXX | XXX | XXX | XXX |
| Evotec | XXX | XXX | XXX | XXX | XXX | XXX |
| PolyPeptide | XXX | XXX | XXX | XXX | XXX | XXX |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sino Biological M&A Activity
Sino Biological acquired XXX companies to date.
Last acquisition by Sino Biological was on XXXXXXXX, XXXXX. Sino Biological acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sino Biological
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSino Biological Investment Activity
Sino Biological invested in XXX companies to date.
Sino Biological made its latest investment on XXXXXXXX, XXXXX. Sino Biological invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sino Biological
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sino Biological
| When was Sino Biological founded? | Sino Biological was founded in 2016. |
| Where is Sino Biological headquartered? | Sino Biological is headquartered in China. |
| Is Sino Biological publicly listed? | Yes, Sino Biological is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Sino Biological? | Sino Biological trades under 301047 ticker. |
| When did Sino Biological go public? | Sino Biological went public in 2021. |
| Who are competitors of Sino Biological? | Sino Biological main competitors are AbCellera, ACROBiosystems, Evotec, PolyPeptide. |
| What is the current market cap of Sino Biological? | Sino Biological's current market cap is $1B. |
| What is the current revenue of Sino Biological? | Sino Biological's last fiscal year revenue is $103M. |
| What is the current EV/Revenue multiple of Sino Biological? | Current revenue multiple of Sino Biological is 8.6x. |
| Is Sino Biological profitable? | No, Sino Biological is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.